Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
The White House has issued an Executive Order to accelerate research and access to psychedelic treatments for mental health conditions, which Compass Pathways welcomes as a step towards making their investigational treatment COMP360 available to patients. Compass Pathways is a biotechnology company developing COMP360, a synthetic psilocybin treatment for treatment-resistant depression.
The White House has issued an Executive Order aimed at accelerating the development and approval of treatments for serious mental illnesses, including the potential use of psychedelics. Compass Pathways, a biotechnology company, has welcomed this move, citing its own progress in developing COMP360, a synthetic psilocybin treatment for treatment-resistant depression. COMP360 has shown statistically significant and clinically meaningful results in two phase 3 trials, demonstrating rapid and durable effects. The company is working with the FDA on a rolling submission and review for COMP360. The Executive Order could lead to accelerated regulatory and rescheduling processes for COMP360 if it is approved.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.